Sartorius AG/ADR Business Summary

Sartorius AG (SOAGY) operates as a premier life sciences partner, generating revenue through a high-margin "razor-and-blade" model centered on its two core segments: Bioprocess Solutions (BPS) and Lab Products & Services (LPS). The BPS division, which contributes approximately 80% of total group revenue, provides integrated technologies for the development and manufacture of biopharmaceuticals, including single-use bioreactors, cell culture media, and filtration systems. The LPS division focuses on laboratory instrumentation and bioanalytics for drug discovery and quality control. As of early 2026, the company has successfully transitioned from post-pandemic inventory corrections to a normalized growth trajectory, leveraging a significant recurring revenue stream from consumables. Sartorius maintains a specialized pure-play market position against diversified conglomerates such as Danaher (Cytiva), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), and Repligen, distinguishing itself through a deep technical focus on the efficiency of biologics and advanced therapy manufacturing. Founded in 1870 by Florenz Sartorius, the company is currently led by CEO Dr. Michael Grosse, who assumed the role in July 2025 following the two-decade tenure of Joachim Kreuzburg. Grosse brings extensive experience in process and packaging solutions from his previous leadership at Syntegon Technology. The executive team is further strengthened by CFO Dr. Florian Funck, an expert in financial strategy and M&A from the Haniel Group, alongside divisional heads Dr. René Fáber (BPS) and Dr. Alexandra Gatzemeyer (LPS). Strategic stability is anchored by the Sartorius family, which retains a majority of voting rights through a long-term trust, while Bio-Rad Laboratories remains a notable minority shareholder. The Supervisory Board, chaired by Dr. Lothar Kappich, provides oversight focused on the firm’s dual commitment to scientific innovation and sustainable operational excellence.